📊 BBIO Key Takeaways
Investment Thesis
BridgeBio exhibits severe financial distress with negative stockholders' equity of -$2.1B, indicating liabilities exceed assets by a significant margin. Despite 126% revenue growth, the company is deeply unprofitable with a -144.4% net margin and burning -$447M in free cash flow annually, raising serious questions about operational viability and cash runway.
BBIO Strengths
- Strong revenue growth of 126% YoY demonstrates market traction and commercial progress
- Adequate current ratio of 2.77x suggests near-term liquidity to cover immediate obligations
- Substantial cash position of $570.1M provides runway for operations and development
BBIO Risks
- Negative stockholders' equity of -$2.1B indicates capital structure distress and potential insolvency risk
- Operating cash burn of -$445.9M annually with negative free cash flow trajectory threatens long-term viability
- Net losses of -$724.9M with -144.4% net margin show business model is not generating sustainable profitability despite revenue growth
- Long-term debt of $2.0B combined with negative equity creates significant refinancing and default risk
- Deteriorating profitability per diluted EPS (-$3.78) despite revenue growth indicates inability to translate sales into value creation
Key Metrics to Watch
- Cash burn rate and months of cash runway remaining
- Path to operating profitability and EBITDA inflection
- Debt covenant compliance and refinancing requirements
- Gross margin expansion as revenue scales
- Working capital management and operating cash flow trends
BBIO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.77x current ratio provides a solid financial cushion.
BBIO Profitability Ratios
BBIO vs Healthcare Sector
How BridgeBio Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BBIO Balance Sheet & Liquidity
BBIO 5-Year Financial Trend
5-Year Trend Summary: BridgeBio Pharma, Inc.'s revenue has grown significantly by 620% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.95 indicates the company is currently unprofitable.
BBIO Growth Metrics (YoY)
BBIO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.7M | -$164.3M | $-0.86 |
| Q2 2025 | $2.2M | -$75.5M | $-0.39 |
| Q1 2025 | $116.6M | -$36.2M | $-0.20 |
| Q3 2024 | $2.7M | -$164.3M | $-0.86 |
| Q2 2024 | $1.6M | -$75.5M | $-0.39 |
| Q1 2024 | $1.8M | -$36.2M | $-0.20 |
| Q3 2023 | $338.0K | -$140.2M | $-0.93 |
| Q2 2023 | $1.6M | -$2.6M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BBIO Capital Allocation
BBIO SEC Filings
Access official SEC EDGAR filings for BridgeBio Pharma, Inc. (CIK: 0001743881)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773952086.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/wk-form4_1773698710.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773346534.xml | View → |
| Mar 6, 2026 | 4 | xslF345X05/wk-form4_1772834274.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/wk-form4_1772572630.xml | View → |
❓ Frequently Asked Questions about BBIO
What is the AI rating for BBIO?
BridgeBio Pharma, Inc. (BBIO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BBIO's key strengths?
Strong revenue growth of 126% YoY demonstrates market traction and commercial progress. Adequate current ratio of 2.77x suggests near-term liquidity to cover immediate obligations.
What are the risks of investing in BBIO?
Negative stockholders' equity of -$2.1B indicates capital structure distress and potential insolvency risk. Operating cash burn of -$445.9M annually with negative free cash flow trajectory threatens long-term viability.
What is BBIO's revenue and growth?
BridgeBio Pharma, Inc. reported revenue of $502.1M.
Does BBIO pay dividends?
BridgeBio Pharma, Inc. pays dividends, with $1.0M distributed to shareholders in the trailing twelve months.
Where can I find BBIO SEC filings?
Official SEC filings for BridgeBio Pharma, Inc. (CIK: 0001743881) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BBIO's EPS?
BridgeBio Pharma, Inc. has a diluted EPS of $-3.78.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.